{
    "clinical_study": {
        "@rank": "119243", 
        "acronym": "MAPSS", 
        "arm_group": [
            {
                "arm_group_label": "Saxagliptin", 
                "arm_group_type": "Active Comparator", 
                "description": "5-mg saxagliptin tablet once per day for maximum of 45 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "5-mg tablet once per day for a maximum of 45 days"
            }
        ], 
        "brief_summary": {
            "textblock": "Individuals with type 2 diabetes mellitus (T2DM) are at increased risk for cardiovascular\n      events (for example, heart attack) and the risk is related to one's overall control of blood\n      glucose levels.  In this study the investigators will measure the effects of saxagliptin,\n      compared to placebo, before, during, and after coronary artery bypass graft (CABG) surgery.\n      The investigators will use samples of the patients' blood and tissue to measure and evaluate\n      indicators of the body's response to the treatment.  This study is being done to evaluate\n      the effect of saxagliptin on biomarkers of the heart to help us understand whether reducing\n      or controlling a person's blood glucose levels during and after CABG surgery will produce\n      better clinical outcomes (for example, better heart health)."
        }, 
        "brief_title": "Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Type 2 Diabetes Mellitus", 
            "Cardiovascular Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cardiovascular Diseases", 
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is a randomized, double-blind, placebo-controlled clinical trial to evaluate the\n      effect of saxagliptin on cardiac biomarkers of myocardial necrosis, cardiac function,\n      inflammation, and apoptosis in subjects with Type 2 diabetes mellitus (T2DM) undergoing CABG\n      surgery (on pump, via a median sternotomy approach) as an integrated measure of the\n      potential mechanistic effects of saxagliptin on prevention of CV outcomes. Approximately 74\n      subjects will be randomized and complete the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Known diagnosis of type 2 diabetes mellitus (T2DM) with glycosylated hemoglobin\n             (HbA1c) between 6.5% and 10%, inclusive.\n\n               -  Stable doses of oral antihyperglycemic agents for at least 2 months\n\n               -  Stable dose of chronic insulin therapy for at least 2 months\n\n               -  HbA1c documented within 3 months before study enrollment\n\n          -  Planned first elective coronary artery bypass graft (CABG) surgery\n\n        Exclusion Criteria:\n\n          -  Elevated Creatine Kinase-MB or troponin level above the 99th percentile at screening\n\n          -  Receiving incretin therapy or having received incretin therapy within the previous 2\n             months\n\n          -  Type 1 DM or a history of ketoacidosis\n\n          -  Women who are pregnant or breastfeeding\n\n          -  Known end-stage Kidney disease\n\n          -  Known sensitivity or intolerance to saxagliptin or DPP-4 inhibitor\n\n          -  Clinically apparent liver disease\n\n          -  History of pancreatitis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01765270", 
            "org_study_id": "Pro00041744"
        }, 
        "intervention": {
            "arm_group_label": "Saxagliptin", 
            "description": "one 5-mg saxagliptin tablet or matching placebo daily", 
            "intervention_name": "Saxagliptin", 
            "intervention_type": "Drug", 
            "other_name": "Onglyza"
        }, 
        "intervention_browse": {
            "mesh_term": "Saxagliptin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Diabetes", 
            "Diabetes Mellitus", 
            "Type 2 Diabetes", 
            "Cardiovascular Disease", 
            "Coronary Artery Bypass Surgery"
        ], 
        "lastchanged_date": "February 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35243"
                    }, 
                    "name": "Cardio-Thoracic Surgeons PC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35211"
                    }, 
                    "name": "Cardiology, PC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Huntsville", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35801"
                    }, 
                    "name": "Heart Center Research, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Smith", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72901"
                    }, 
                    "name": "Sparks Regional Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Little Rock", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72205"
                    }, 
                    "name": "Arkansas Cardiology, PA"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palo Alto", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94304"
                    }, 
                    "name": "Stanford University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "Emory University Hospital Midtown"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center (DUMC)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23225"
                    }, 
                    "name": "Chippenham Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "West Virginia", 
                        "zip": "25304"
                    }, 
                    "name": "Charleston Area Medical Center (CAMC)"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial", 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "L.  Kristin Newby, M.D., MHS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the effect of saxagliptin on cardiac biomarkers of myocardial necrosis in subjects with T2DM undergoing CABG (on pump, via a median sternotomy approach) as one measure of the potential mechanistic effects of saxagliptin on prevention of cardiovascular (CV) outcomes.", 
            "measure": "The effect of saxagliptin on cardiac biomarkers", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 5-7 days of study treatment, intraop, post-op, discharge, and 30 days of study treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01765270"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To evaluate the effect of saxagliptin on clinical and biomarker variables and safety as an integrated measure of the potential mechanistic actions of saxagliptin on prevention of CV outcomes.", 
            "measure": "The effect of saxagliptin on clinical and biomarker variables and safety", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline, 5-7 days of study treatment, intraop, post-op, discharge, and 30 days of study treatment"
        }, 
        "source": "Duke University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "January 2014", 
        "why_stopped": "The study was stopped due to poor enrollment."
    }
}